Login / Signup

Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia.

Riccardo MoiaRiccardo DondolinMaria Stefania De ProprisDonatella TalottaSamir MouhssineFrancesca PerutelliGianluigi RedaVeronica MattielloGian Matteo RigolinMarina MottaJacopo OlivieriRenato FaninOmar PerbelliniIsacco FerrariniFrancesca Romana MauroIlaria Del GiudiceLuca LaurentiAnnamaria TomassoMassimo GentileAnna Maria FrustaciAlessandra TedeschiAlessandro GozzettiCaterina StelitanoChiara RusconiCarol MorenoFrancesco ForconiRoberto MarascaMarta CosciaDavide RossiRobin FoàGianluca Gaidano
Published in: Hematological oncology (2022)
Keyphrases
  • chronic lymphocytic leukemia
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • peritoneal dialysis
  • prognostic factors
  • cross sectional
  • double blind